MedTrace Logo

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

NCT02283749 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-02-02

Study results available
· View outcomes & findings →

Summary

In this study patient's will receive the medicine Xofigo which is a radioactive drug that is FDA approved to treat prostate cancer that has spread to the bones. Xofigo has not previously been tested to treat lung cancer that has spread to the bones. Your doctors are studying the effects, good and bad, of Xofigo when used to treat lung cancer that has spread to the bones.

Conditions

  • Non Small Cell Lung Cancer With Bone Metastatses

Interventions

BIOLOGICAL

Xofigo

This is a radio-isotope

Sponsors & Collaborators

  • Rhode Island Hospital

    collaborator OTHER

  • The Miriam Hospital

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Angela Taber MD

    lead OTHER

Principal Investigators

  • Howard Safran, MD · BrUOG Study Chair

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-07-05
Completion
2018-11-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283749 on ClinicalTrials.gov